Patents Represented by Attorney, Agent or Law Firm John P. White
-
Patent number: 6533999Abstract: Ozone generated from an ozonizer is added to a polluted gas containing harmful substances, which is generated from a polluted gas source. Then, the ozone-added polluted gas is allowed to flow through an adsorbing layer containing a high-silica adsorbent that adsorbs both ozone and harmful substances. The harmful substances contained in the polluted gas are converted into harmless substances within the adsorbing layer by the action of the ozone.Type: GrantFiled: April 1, 1999Date of Patent: March 18, 2003Assignee: Mitsubishi Heavy Industries, Ltd.Inventors: Jun Izumi, Akinori Yasutake, Nariyuki Tomonaga, Hiroyuki Tsutaya
-
Patent number: 6532803Abstract: A detection assembly for detecting moisture within an unsaturated permeable soil or soil-like medium is disclosed which includes a funnel 11 having a surface inclined in use to the vertical for distorting the flow streamlines within the medium to cause an increase in fluid content and saturation at points in the permeable medium; a cup 13 beneath the funnel for collecting free fluid from the saturated permeable medium; a sensor 14 for detecting the presence of free fluid formed upon saturation within the permeable medium, and a vent 16 for venting air from said collection means.Type: GrantFiled: August 27, 1999Date of Patent: March 18, 2003Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Paul Andrew Hutchinson, Richard Stirzaker
-
Patent number: 6531471Abstract: This invention is directed to morpholinone and morpholine derivatives which are selective antagonists for human &agr;1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the &agr;1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: December 14, 2001Date of Patent: March 11, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Bharat Lagu, Dhanapalan Nagarathnam, Dake Tian, Charles Gluchowski
-
Patent number: 6531291Abstract: The present invention provides a method of selecting a compound which inhibits the enzymatic activity of enoyl reductase which comprises: (A) contacting enoyl reductase with the compound linked to an acyl carrier protein; (B) measuring the enzymatic activity of the entoy reductase of step (A) compared with the enzymatic activity of enoyl reductase in the absence of the compound and selecting the compound which inhibits the enzymatic activity of enoyl reductase.Type: GrantFiled: November 10, 1999Date of Patent: March 11, 2003Assignees: The Trustees of Columbia University in the City of New York, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Christina Kabbash, Samuel C. Silverstein, Howard A. Shuman, John S. Blanchard
-
Patent number: 6528024Abstract: An ozone storage/recovery method comprises a process for supplying an ozone-containing gas, generated by an ozone generator, to an ozone adsorbent tank filled with an ozone adsorbent contained at least one high-silica material selected from the group consisting of a high-silica pentasil zeolite, a dealumination faujasite and a mesoporous silicate, causing the adsorbent to adsorb ozone at a temperature of 0° C. or below, and storing the ozone, and a process for desorbing the ozone adsorbed by the adsorbent in the ozone adsorbent tank and recovering the ozone from the adsorbent tank, whereby ozone can be supplied as required.Type: GrantFiled: March 13, 2001Date of Patent: March 4, 2003Assignee: Mitsubishi Heavy Industries, Ltd.Inventors: Jun Izumi, Akinori Yasutake, Nariyuki Tomonaga, Hiroyuki Tsutaya
-
Patent number: 6527692Abstract: A radiation catheter for intraluminal treatment of a patient has a plurality of separably inflatable and deflatable balloon segments located along the length of the catheter, and a radiation source within a lumen of the catheter. As the radiation source is moved, one or more balloon segments closest to the source is inflated with the remainder deflated thereby allowing blood to perfuse in areas where inflation of the segments is not needed to effect centering of the source in the luminal structure.Type: GrantFiled: November 19, 1999Date of Patent: March 4, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventor: Judah Z. Weinberger
-
Patent number: 6528685Abstract: Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid.Type: GrantFiled: October 19, 1999Date of Patent: March 4, 2003Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.Inventors: Sasson Cohen, Yaacov Herzig, Ruth Levy, Mitchell Shirvan, Jeff Sterling, Alex Veinberg, Moussa B. H. Youdim, John P. M. Finberg
-
Patent number: 6528646Abstract: The synthesis of C11N5 marine sponge alkaloids (±)-hymenin (1), stevensine (2), hymenialdisine (3), and debromohymenialdisine (4) is described. These natural products are the primary family members of the sponge metabolites that contain a fused pyrrolo[2,3-c]lazepin-8-one ring system with either a 2-aminoimidazole (AI) or glycocyamidine appendage. The key steps in the synthesis centered around the generation of novel azafulvenium ions and their regioselective heterodimerization with AI in order to create the tricyclic core. A rarely used protodebromination/oxidation strategy was employed to selectively generate the desired a-bromo substitution pattern seen in hymenialdisine (3). In addition, the AI moiety was shown to be a useful precursor to the glycocyamidine unit found in 3 and 4, which suggests that AI derived natural products may be the biogenic forerunners to glycocyamidine metabolites.Type: GrantFiled: December 28, 2000Date of Patent: March 4, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: David A. Horne, Kenichi Yakushijin
-
Patent number: 6521416Abstract: The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH&bgr;cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH&bgr;cf without substantially cross-reacting with hLH, hLH&bgr; or hLH&bgr;cf, under conditions permitting formation of a complex between the antibody and hLH&bgr;cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH&bgr;cf in the sample; and (c) comprising the amount of hLH&bgr;cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH&bgr;cf in the sample similar to the amount of hLH&bgr;cf in the known postmenopausal sample indicates temporal proximity to the onset of menopaType: GrantFiled: August 1, 2000Date of Patent: February 18, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Steven Birken, Yacov Maydelman, Galina I. Kovalevskaya, John F. O'Connor
-
Patent number: 6514938Abstract: The present invention provides molecular weight markers for accurate determination of the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and molecular weight, and between retention time and the log of the molecular weight. The molecular weight markers also optimally demonstrate biological activity similar to glatiramer acetate or corresponding copolymers and can be used for treating or preventing various immune diseases. In addition, the subject invention provides pharmaceutical compositions for the treatment of immune diseases comprising a polypeptide having an identified molecular weight and an amino acid composition corresponding to glatiramer acetate or a terpolymer.Type: GrantFiled: September 24, 1999Date of Patent: February 4, 2003Assignee: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Alexander Gad, Dora Lis
-
Patent number: 6509190Abstract: The present invention provides for a recombinant DNA construct for expressing a gene of interest comprising a mouse calcium-calmodulin-dependent kinase IIá promoter operatively linked to a gene of interest. The present invention also provides for a murine neuronal cell line which has been stably transformed with the recombinant DNA construct.Type: GrantFiled: November 12, 1997Date of Patent: January 21, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Eric R. Kandel, Mark Mayford
-
Patent number: 6503759Abstract: Encoded combinatorial chemistry is provided, where sequential synthetic schemes are recorded using organic molecules, which define choice of reactant, and stage, as the same or different bit of information. Various products can be produced in the multi-stage synthesis, such as oligomers and synthetic non-repetitive organic molecules. Conveniently, nested families of compounds can be employed as identifiers, where number and/or position of a substituent define the choice. Alternatively, detectable functionalities may be employed, such as radioisotopes, fluorescers, halogens, and the like, where presence and ratios of two different groups can be used to define stage or choice. Particularly, pluralities of identifiers may be used to provide a binary or higher code, so as to define a plurality of choices with only a few detachable tags. The particles may be screened for a characteristic of interest, particularly binding affinity, where the products may be detached from the particle or retained on the particle.Type: GrantFiled: February 7, 1997Date of Patent: January 7, 2003Assignees: The Trustees of Columbia University in the City of New York, Cold Spring Harbor LaboratoryInventors: W. Clark Still, Michael H. J. Ohlmeyer, Lawrence W. Dillard, John C. Reader, Michael H. Wigler
-
Patent number: 6503469Abstract: A polluted fluid, such as exhaust gas from a refuse incinerator, containing at least one pollutant, such as volatile organic compounds (VOCs), SOx or NOx, is processed by passing the polluted fluid through an adsorbing layer containing a high-silica adsorbent capable of adsorbing both ozone and at least one pollutant to adsorb at least one pollutant on the adsorbent. Then, ozone is brought into contact with the adsorbing layer to oxidize and decompose the pollutant adsorbed on the adsorbent, while stopping the flow of the polluted fluid.Type: GrantFiled: June 22, 1999Date of Patent: January 7, 2003Assignee: Mitsubishi Heavy Industries, Ltd.Inventors: Jun Izumi, Akinori Yasutake, Nariyuki Tomonaga, Hiroyuki Tsutaya
-
Patent number: 6500663Abstract: This invention provides an isolated DNA molecule which is at least 30 nucleotides in length and which uniquely defines a herpesvirus associated with Kaposi's sarcoma. This invention provides an isolated herpesvirus associated with Kaposi's sarcoma. This invention provides an isolated peptide encoded by the isolated DNA molecule. Further, this invention provides an isolated DNA virus wherein the viral DNA is about 270 kb in size; wherein the DNA encodes a thymidine kinase; and wherein the viral DNA is capable of selectively hybridizing to a nucleic acid probe selected from the group consisting of SEQ. ID NOs:10-12. This invention provides an antibody specific to the peptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a transgenic nonhuman mammal and a cell line containing at least a portion of the isolated DNA molecule.Type: GrantFiled: March 6, 2000Date of Patent: December 31, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: Yuan Chang, Patrick S. Moore
-
Patent number: 6500627Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: February 3, 1998Date of Patent: December 31, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 6498177Abstract: This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: September 28, 2001Date of Patent: December 24, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Yoon T. Jeon, Charles Gluchowski
-
Patent number: 6495583Abstract: This invention provides compounds having the structure: wherein each of R1, R2, R3 and R9 is independently H; straight chain or branched, substituted or unsubstituted C1-C7 alkyl, C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl or cycloalkenyl; acyl, phenyl, substituted phenyl, or heteroaryl; wherein each dashed line represents a single bond or a double bond with the proviso that if R1 is present, R3 is absent and there is a double bond between N at position 3 and C at position 2 and a single bond between C at position 2 and N at position 1 and if R3 is present, R1 is absent and there is a double bond between N at position 1 and C at position 2 and a single bond between C at position 2 and N at position 3; wherein each of R4, R5 and R6 is independently H, F, Cl, Br, I; straight chain or branched, substituted or unsubstituted C1-C7 alkyl, C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl or cycloalkenyl; phenyl, substituted phenyl, heteroaryl, —OH, —OR,, —CN, —COR,, —CO2R7,Type: GrantFiled: May 6, 2002Date of Patent: December 17, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Yoon T. Jeon, Charles Gluchowski
-
Patent number: 6492426Abstract: The subject invention provides a method of treating mania in bipolar disorder in a subject comprising administering to the subject a therapeutically effective amount of derivatives of 1-aminoindan or their racemic mixtures, enantiomers, or salts, of the general formula: wherein n is 0 or 1; each of R1 and R2 are hydrogen, C1-C4 alkyl, halogen; R3 is hydrogen, C1-C4 alkyl, hydroxy, C1-C4 alkoxy; R4 is hydrogen, C1-C4 alkyl; R6 is hydrogen, substituted or unsubstituted C1-C12 alkyl, C6-C12 aryl, C7-C12 aralkyl or A—N—R9R10, provided that R6 is not methyl when R1, R2, R3 and R4 are hydrogen atoms, wherein A is substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted C7-C12 aralkyl, and each of R9 and R10 are independently hydrogen, C1-C12 alkyl, C6-C12 aryl, C7-C12 aralkyl, COOtBu, or indanyl; and racemic mixtures, enantiomers, and salts thereof.Type: GrantFiled: October 27, 2000Date of Patent: December 10, 2002Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Gabriela Barak, Ruth Levy
-
Patent number: 6489125Abstract: This invention provides methods of regulating contraction of a subject's heart and of treating heart failure and cardiac arrhythmia. This invention also provides methods of obtaining compounds that bind to, and activate or inhibit the activation of a type 2 ryanodine (RyR2) receptor, and methods for screening for compounds that alleviate heart disease.Type: GrantFiled: May 10, 2000Date of Patent: December 3, 2002Assignee: The Trustees of Columbia University In The City of New YorkInventors: Andrew R. Marks, Steven O. Marx
-
Patent number: 6489459Abstract: This invention provides an isolated nucleic acid molecule which encodes a wildtype or mutated HOP-1. This invention also provides a purified wild-type HOP-1 protein or a purified mutated HOP-1 protein. This invention also provides a method for production of an antibody capable of binding to wild-type HOP-1 or mutated HOP-1 protein. This invention also provides an antibody capable of specifically binding to wild-type HOP-1 or mutated HOP-1. This invention also provides a transgenic animal comprising the isolated nucleic molecule encoding HOP-This invention also provides Caenorhabditis elegans mutants in the endogenous hop-1 gene and various method to produce such mutants. This invention also provides a method for identifying a compound which is capable of ameliorating Alzheimer's disease. This invention also provides a method for determining whether a compound is capable of ameliorating Alzheimer's disease. This invention also provides a method for producing suppressors of a hop-1 allele.Type: GrantFiled: September 25, 1997Date of Patent: December 3, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: Iva Greenwald, Xiajun Li